{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:45:00Z","timestamp":1778039100408,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1H0541"],"award-info":[{"award-number":["CMRPD1H0541"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-105-2410-H-182-018"],"award-info":[{"award-number":["MOST-105-2410-H-182-018"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vhri.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:39:21Z","timestamp":1663270761000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan"],"prefix":"10.1016","volume":"32","author":[{"given":"Hung-Hsueh","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaya","family":"Sukarom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pavelyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2022.06.006_bib2","unstructured":"FDA COVID-19 response. https:\/\/www.fda.gov. US Food & Drug Administration. Accessed November 2,\u00a02017."},{"key":"10.1016\/j.vhri.2022.06.006_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"9","key":"10.1016\/j.vhri.2022.06.006_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ijc.22538","article-title":"Human papillomavirus genotype in cervical cancer: a population-based study","volume":"120","author":"Lai","year":"2007","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.vhri.2022.06.006_bib7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/sj.bjc.6605974","article-title":"Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system","volume":"103","author":"Chow","year":"2010","journal-title":"Br J Cancer"},{"issue":"42","key":"10.1016\/j.vhri.2022.06.006_bib9","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vhri.2022.06.006_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vhri.2022.06.006_bib11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jval.2015.08.010","article-title":"Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic bayesian methodology: the BEST II study","volume":"18","author":"Haeussler","year":"2015","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vhri.2022.06.006_bib12","first-page":"1794","article-title":"Projected impact of Cervarix\u00ae vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom [retracted in: Van Effelterre TP, Hogea C, Taylor SM. Hum Vaccin Immunother. 2014;10(9):2776]","volume":"10","author":"Van Effelterre","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vhri.2022.06.006_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/21645515.2016.1140288","article-title":"The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model","volume":"12","author":"Chesson","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vhri.2022.06.006_bib14","first-page":"459","article-title":"The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan","volume":"9","author":"Dasbach","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.vhri.2022.06.006_bib15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","article-title":"Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan","volume":"15","author":"Demarteau","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2022.06.006_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1472-6963-10-11","article-title":"Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.vhri.2022.06.006_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.31557\/APJCP.2019.20.5.1377","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan","volume":"20","author":"Tang","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.vhri.2022.06.006_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","article-title":"An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany","volume":"17","author":"Largeron","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2022.06.006_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3802\/kjgo.2007.18.3.209","article-title":"Sexual behavior of Korean young women: preliminary study for the introducing of HPV prophylactic vaccine","volume":"18","author":"Kim","year":"2007","journal-title":"Korean J Gynecol Oncol"},{"issue":"9576","key":"10.1016\/j.vhri.2022.06.006_bib24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vhri.2022.06.006_bib25","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.vhri.2022.06.006_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.vhri.2022.06.006_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9574","key":"10.1016\/j.vhri.2022.06.006_bib28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vhri.2022.06.006_bib29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2022.06.006_bib30","series-title":"Vaccines for the 21st Century: A\u00a0Tool for Decisionmaking","article-title":"Division of Health Promotion and Disease Prevention, Committee to Study Priorities for Vaccine Development","author":"Institute of Medicine","year":"2000"},{"key":"10.1016\/j.vhri.2022.06.006_bib31","unstructured":"Myers E, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Abstract No. 390.2. Mexico City; 2004."},{"issue":"1","key":"10.1016\/j.vhri.2022.06.006_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vhri.2022.06.006_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.vhri.2022.06.006_bib35","first-page":"65","article-title":"Stress and quality of life following cervical cancer","volume":"21","author":"Andersen","year":"1996","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"6","key":"10.1016\/j.vhri.2022.06.006_bib36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.vhri.2022.06.006_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ygyno.2005.01.010","article-title":"Quality of life in long-term cervical cancer survivors","volume":"97","author":"Wenzel","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"7-8","key":"10.1016\/j.vhri.2022.06.006_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.20452\/pamw.945","article-title":"Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study","volume":"120","author":"Golicki","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.vhri.2022.06.006_bib40","series-title":"Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis","year":"2003"},{"key":"10.1016\/j.vhri.2022.06.006_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.epidem.2013.11.002","article-title":"Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy","volume":"6","author":"Gilbert","year":"2014","journal-title":"Epidemics"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:52Z","timestamp":1761941572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"alternative-id":["S2212109922001315"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.06.006","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}